In Depth 22 Oct 2025 PCSK9’s second act: From antibodies to gene editing With Eli Lilly’s recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents. October 22, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 3 Jun 2025 How biotechs are developing novel treatments to tackle high cholesterol Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets. June 3, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 10 May 2024Cytokinetics’ cardiovascular pipeline beats strong Discover Cytokinetics’ groundbreaking cardiovascular treatments, including heart drug aficamten, in our latest podcast with CEO Robert Blum. May 10, 2024 Share WhatsApp Twitter Linkedin Email
In Depth 8 May 2024 New treatment for pulmonary hypertension: what biotech holds in store? While it has been about managing pulmonary hypertension’s symptoms for a long time, new treatments are adressing the root of the disease. May 8, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 4 Jan 2024 Can GLP-1 agonists, the miraculous obesity drugs, treat cardiovascular diseases? Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases. January 4, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 10 Nov 2023How biotech can mend a broken heart CellProthera has been working to do the impossible – mend broken hearts. The biotech company’s ProtheraCytes cell therapy regenerates damaged tissue following a heart attack, thus restoring cardiac function. In this podcast, we investigate regenerative therapy with CellProthera’s CEO, Matthieu de Kalbermatten. While regenerative cell therapy is dependent on the patient’s own cells, and reliant […] November 10, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jul 2023 Lilly boosts obesity portfolio with Versanis Bio acquisition Eli Lilly and Company is set to acquire Versanis Bio in a deal that could be worth close to $2 billion. Versanis Bio is a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II […] July 17, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Jun 2023 Six companies that have made their name in the cardiovascular space Cardiovascular disease is a general term used to describe a disease that affects the heart and blood vessels. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, with statistics from 2019 stating that an estimated 17.9 million people died from some type of cardiovascular disease, making up 32% […] June 8, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 19 May 2023 Can cardiovascular diseases be cured? The future of heart treatment Cardiovascular diseases, characterized as a group of disorders of the heart and blood vessels, are the leading cause of death worldwide. In fact, in the U.S. alone, it is thought that one person dies every 33 seconds from cardiovascular disease. Although clearly a huge health problem throughout the world, developing cures for cardiovascular diseases is […] May 19, 2023 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 26 Apr 2023 LincRNA discovery could lead to targeted treatments Our genetic code includes more than 15,000 specific sections that can be made into molecules called lincRNAs. Some of these sections can occur in coiled-up sections of our genome called topologically associating domains, or TADs. LincRNAs derived from TADs appear to act as markers indicating the specific kind of tissue they are within. When something […] April 26, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2023 Calida Therapeutics launches to tackle thrombo-inflammatory disorders Calida Therapeutics, a preclinical stage biotech company specializing in thrombo-inflammatory disorders, has announced its incorporation in Paris, France. Calida Therapeutics has already raised €2 million ($2.17 million) in seed funding from venture capital company AdBio partners. The funds will be used to conduct additional in vivo proofs of concept and select a lead candidate. Calida […] April 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2023 Destiny Pharma gel reduces nasal staph in surgery patients Destiny Pharma has revealed data showing its drug reduced Staphylococcus aureus in the nasal passage of pre-op cardiac surgery patients. Destiny Pharma is a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections. The data was published in the journal Infection Control & Hospital Epidemiology. The paper was […] March 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email